KYUNG DONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,410 KRW | -0.16% |
|
+1.42% | -3.03% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,69,932 | 1,87,532 | 3,10,369 | 3,13,540 | 2,13,543 | 1,79,354 |
| Enterprise Value (EV) 1 | 1,87,050 | 1,20,470 | 2,50,784 | 2,67,826 | 1,95,284 | 1,62,653 |
| P/E ratio | 51.4 x | 9.32 x | 22.1 x | 24.9 x | 17.6 x | -8.66 x |
| Yield | 2.63% | 5.05% | 4.46% | 4.37% | 5.08% | 6.05% |
| Capitalization / Revenue | 1.51 x | 1.06 x | 1.79 x | 1.77 x | 1.17 x | 1.1 x |
| EV / Revenue | 1.04 x | 0.68 x | 1.44 x | 1.51 x | 1.07 x | 1 x |
| EV / EBITDA | 6.88 x | 3.87 x | 9.75 x | 11.8 x | 13 x | -8.51 x |
| EV / FCF | 4.97 x | -61 x | -31 x | 41.9 x | -70.4 x | 319 x |
| FCF Yield | 20.1% | -1.64% | -3.22% | 2.39% | -1.42% | 0.31% |
| Price to Book | 1.27 x | 0.83 x | 1.18 x | 1.2 x | 0.83 x | 0.79 x |
| Nbr of stocks (in thousands) | 23,678 | 23,678 | 27,712 | 27,383 | 27,134 | 27,134 |
| Reference price 2 | 11,400 | 7,920 | 11,200 | 11,450 | 7,870 | 6,610 |
| Announcement Date | 11/03/19 | 13/03/20 | 19/03/21 | 21/03/22 | 22/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,79,316 | 1,76,500 | 1,73,828 | 1,77,611 | 1,82,718 | 1,62,674 |
| EBITDA 1 | 27,193 | 31,121 | 25,724 | 22,770 | 15,016 | -19,106 |
| EBIT 1 | 20,385 | 24,155 | 18,950 | 15,758 | 8,312 | -24,955 |
| Operating Margin | 11.37% | 13.69% | 10.9% | 8.87% | 4.55% | -15.34% |
| Earnings before Tax (EBT) 1 | 20,233 | 34,945 | 19,339 | 18,432 | 17,941 | -18,503 |
| Net income 1 | 5,242 | 20,126 | 12,459 | 12,672 | 12,161 | -20,708 |
| Net margin | 2.92% | 11.4% | 7.17% | 7.13% | 6.66% | -12.73% |
| EPS 2 | 221.8 | 850.0 | 507.8 | 460.4 | 447.0 | -763.2 |
| Free Cash Flow 1 | 37,643 | -1,973 | -8,079 | 6,388 | -2,773 | 510.2 |
| FCF margin | 20.99% | -1.12% | -4.65% | 3.6% | -1.52% | 0.31% |
| FCF Conversion (EBITDA) | 138.43% | - | - | 28.05% | - | - |
| FCF Conversion (Net income) | 718.08% | - | - | 50.41% | - | - |
| Dividend per Share 2 | 300.0 | 400.0 | 500.0 | 500.0 | 400.0 | 400.0 |
| Announcement Date | 11/03/19 | 13/03/20 | 19/03/21 | 21/03/22 | 22/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 82,882 | 67,062 | 59,585 | 45,714 | 18,259 | 16,701 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 37,643 | -1,973 | -8,079 | 6,388 | -2,773 | 510 |
| ROE (net income / shareholders' equity) | 2.43% | 10.1% | 5.17% | 4.83% | 4.68% | -8.53% |
| ROA (Net income/ Total Assets) | 5% | 5.54% | 4.09% | 3.38% | 1.72% | -5.17% |
| Assets 1 | 1,04,760 | 3,63,522 | 3,04,536 | 3,75,288 | 7,05,159 | 4,00,603 |
| Book Value Per Share 2 | 8,941 | 9,574 | 9,461 | 9,540 | 9,479 | 8,409 |
| Cash Flow per Share 2 | 1,272 | 2,659 | 577.0 | 654.0 | 536.0 | 434.0 |
| Capex 1 | 3,931 | 2,055 | 28,591 | 3,926 | 10,574 | 6,290 |
| Capex / Sales | 2.19% | 1.16% | 16.45% | 2.21% | 5.79% | 3.87% |
| Announcement Date | 11/03/19 | 13/03/20 | 19/03/21 | 21/03/22 | 22/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -3.03% | 13Cr | |
| +21.28% | 4.44TCr | |
| +24.60% | 2.3TCr | |
| +17.78% | 1.51TCr | |
| +12.87% | 1.31TCr | |
| +44.67% | 1.19TCr | |
| -8.33% | 698.92Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +12.22% | 551.54Cr |
- Stock Market
- Equities
- A011040 Stock
- Financials Kyung Dong Pharmaceutical Co., Ltd.